Providing lifesaving technology to cardiac surgery teams around the world
Terumo Cardiovascular Group manufactures and sells medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass and intra-operative monitoring.
A variety of Terumo products are used in cardiovascular surgery settings globally:
Among these, Terumo introduced the world’s first hollow fiber oxygenator in 1982. Through the years, Terumo has continually improved this technology to increase oxygen exchange performance and further reduce patient burden.
Recently, Terumo obtained manufacturing authorization for the world's first regenerative medicine product to treat heart failure – cell sheets derived from human skeletal muscle cells. Work continues to provide heart disease patients with this new treatment option.
Terumo Cardiovascular Group is committed to continuous innovation, pursuing less burdensome cardiovascular surgery to enhance cardiovascular patients’ quality of life.
(Notice) The regulatory approval status and availability of these products differs by country and region.
Terumo offers devices that circulate blood in place of the heart and lungs during cardiovascular surgery in which the heart is stopped (“on pump” surgery).
During open-heart surgery, the heart-lung machine temporarily takes over the pumping function of the heart.
An oxygenator temporarily takes over the functions of the lungs, exchanging gases including oxygen and then returning oxygenated blood back to the patient via the cardiopulmonary bypass circuit.
(Notice) Commercially available only in Japan and some Asian countries.
This system performs the heart and lung functions for a patient who has cardiogenic shock or heart stoppage resulting from acute heart attack. This is done by inserting a catheter into a blood vessel of the thigh to bring blood outside the body, where it is cycled through a centrifugal pump and membrane oxygenator in a closed state.
Beating Heart or Off-pump Coronary Artery Bypass Surgery avoids placing patients on-pump, and surgery is performed while the heart continues to beat. After chest incision, a stabilization system steadies only the portion of heart where the surgeon is working. This type of surgery is designed to avoid complications with on-pump procedures and benefits certain patient populations.
In 2015, Terumo’s HeartSheet autologous skeletal myoblast sheets became the world’s first cardiac regenerative therapy product to be approved for manufacture and sale. Individual skeletal myoblast sheets are made by taking skeletal myoblasts from the patient’s own thigh muscle, culturing them, and then forming them into sheets. HeartSheet autologous skeletal myoblast sheets are applied directly on the heart and are seen as a promising therapy option for patients not likely to benefit from drug therapies or surgical procedures.